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ABSTRACT
Introduction: Glucagon-like peptide-1 (GLP-1)
has many effects on the human body, but its
glucose-lowering effect through its stimulation
of insulin secretion is the most significant. GLP-
1 also acts on renal function and hemodynam-
ics. The antihypertensive and renoprotective
effects of GLP-1 receptor agonists are partly
explained by their vasoactive effect and
increased natriuresis, but their positive influ-
ences on blood pressure and the development
and progression of kidney disease are attributed
to many effects beyond glycemic control. The
aim of this study was to determine how the
native gut hormone GLP-1 influences the
renin–angiotensin–aldosterone system (RAAS).
Methods: Fourteen healthy participants (6
males and 8 females) were included in a double-
blind, placebo-controlled crossover study. After
overnight fasting and oral sodium loading,
participants were randomly assigned to receive
either placebo (500 ml of 0.9% saline) or GLP-1
infusion (1.5 pmol/kg/min dissolved in 500 ml
of 0.9% saline) over a 3-h period. After 3 and
6 h, the following parameters were measured:
glucose, insulin, plasma renin activity, aldos-
terone, GLP-1, and antidiuretic hormone. After
7 days, the protocol was repeated, except that
those who had previously received placebo now
received GLP-1 infusion, and those who had
previously received GLP-1 now received
placebo.
Results: Three hours after GLP-1 infusion,
aldosterone had decreased by a statistically sig-
nificant amount (p\0.008) compared to the
baseline level.
Conclusion: The present study showed that
native GLP-1 can decrease aldosterone secretion
in a group of healthy individuals, supporting
the idea of beneficial outcomes of GLP-1-acti-
vating agents on blood pressure and the RAAS.
Trial Registration: ClinicalTrials.gov Identifier:
NCT02130778.
Keywords: Aldosterone; Diabetes; GLP-1; Kid-
ney; Nephropathy
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INTRODUCTION
Diabetes is the most common cause of end-stage
renal disease in the developed world [1]. The
pathophysiology of diabetic kidney disease is
composite: acquired metabolic and hemody-
namic changes associated with genetic traits
activate prooxidative, proinflammatory, and
profibrotic pathways leading to hyperfiltration.
Hyperfiltration is followed by a gradual decline
in glomerular filtration [2].
The incretin hormone glucagon-like peptide-
1 (GLP-1) is released from intestinal enteroen-
docrine L cells in response to a carbohydrate
meal. GLP-1 has many effects on the human
body, but its glucose-lowering effect due to its
stimulation of insulin secretion is the most
important. GLP-1 acts on renal function and
hemodynamics, and GLP-1 receptors are widely
expressed in many tissues beyond the pancreas,
including the kidneys. In humans, receptors
have been found in large and medium-sized
renal arteries but not in the tubules or glomeruli
[3].
Incretin-based therapy for diabetes lowers
systolic blood pressure, as also confirmed by a
large meta-analysis drawing from six clinical
trials and comprising 2171 subjects treated for
at least 6 years with a GLP-1 receptor agonist-
exenatide [4]. The blood pressure-lowering
effect was later attributed to improved
endothelial dysfunction through the GLP-1
receptor-dependent pathway, stimulating
diuresis and natriuresis [5]. Hypoglycemic
agents that utilize the effect of incretin also
have renoprotective properties independent of
their glucose-lowering effects.
In experimental animal models, exenatide
suppressed the inflammatory mediator nuclear
factor kappa B, reduced substances associated
with abnormalities in vascular function, and
delayed the progression of diabetic renal disease
[6]. Liraglutide, another GLP-1 receptor agonist,
was found to be protective against increased
renal oxidative stress under chronic hyper-
glycemia in GLP-1 knockout mice [7].
In experimental studies, prolonged admin-
istration of exendin-4 (a peptide agonist of GLP-
1) in normal rats resulted in increased plasma
concentrations of aldosterone and corticos-
terone, independent of adrenocorticotropic
hormone (ACTH). In streptozotocin-induced
diabetic rats, exendin-4 increased the plasma
levels of ACTH along with aldosterone and
corticosterone. The effect in normal rats was
attributed to aldosterone and corticosterone
secretion by exendin-4 but is not mediated
through the hypothalamo-hypophyseal axis [8].
The antihypertensive and renoprotective
effects of GLP-1 receptor agonists are partly
explained by their vasoactive effect and the
increased natriuresis that results from their
inhibition of the sodium-hydrogen ion
exchanger in the proximal tubule. Additional
effects on the renin–angiotensin–aldosterone
system (RAAS) may also contribute to renal
benefits [9, 10].
The action of GLP-1 on kidney function is
still not entirely clear, and the few studies that
have been conducted in humans have con-
firmed the previously mentioned natriuretic
effect and the influence on fluid homeostasis
and the RAAS [11–13].
The aim of this study was to investigate the
effect of GLP-1 infusion after oral and intra-
venous sodium loading on kidney hemody-
namics and the RAAS, particularly aldosterone,




The study was conducted at the Department of
Endocrinology, Internal Clinic, University
Hospital Centre Zagreb, and registered at Clin-
icalTrials.gov with the identifier NCT02130778.
All procedures performed in studies involving
human participants were carried out in accor-
dance with the ethics committee of University
Hospital Centre Zagreb and with the 1964 Hel-
sinki Declaration and its later amendments or
comparable ethical standards. Informed con-
sent was obtained from all participants included
in the study.
Fourteen healthy non-obese (BMI\ 30) par-
ticipants (6 males and 8 females, mean age
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33 years, range 29–64 years) were randomized
for a double-blind, placebo-controlled, cross-
over study. The participants within the group of
healthy volunteers were randomized. Sample
size was not calculated prior to the start of the
study. The sample size was in line with those
used in previous studies performed with a sim-
ilar protocol which included 12–16 participants
[11–13].
Table 1 shows the descriptive statistics of
parameters for the study participants measured
at baseline (visit 1).
Inclusion criteria were: age 18–50 years, body
mass index (BMI) 18–27 kg/m2 (for those with
BMI[ 25 kg/m2, fat percentage was normal for
gender and age), and, for women, a low likeli-
hood of conception prior to or during the study.
Participants were healthy, as determined by
fasting blood parameters of the total blood
count, standard biochemistry tests, thyroid-
stimulating hormone, urine chemistry, oral
glucose tolerance test (OGTT), 24-h urine pro-
tein excretion, and glomerular filtration assess-
ment. Standard biochemical methods were
usedto measure laboratory parameters. On the
first visit, the following baseline tests were
administered: fasting glucose and insulin, GLP-
1, aldosterone, PRA (plasma renin activity), and
antidiuretic hormone (ADH).
All participants had normal findings on
standard 12-lead electrocardiogram, kidney
ultrasound, and 24-h blood pressure monitor-
ing. None of the participants had any history of
hypertension, diabetes, kidney disease,
myocardial infarction, cerebrovascular inci-
dents, transient ischemic attack, or malignancy
within the last 5 years; they also were not cur-
rently in a febrile state or pregnant/nursing.
Body composition and hydration were esti-
mated by means of bioelectrical impedance
analysis [total body water (TBW), fat percent-
age, fat mass, muscle mass, and visceral fat
Table 1 Descriptive statistics for parameters measured at baseline (visit 1)
Mean SD Median Minimum Maximum N
Age (years) 35.50 7.62 33.00 26.00 48.00 14
Syst BP (mmHg) 118.57 10.71 115.00 103.00 137.00 14
Dia BP (mmHg) 70.29 10.37 71.00 42.00 85.00 14
Syst dip (mmHg) 12.43 4.26 12.50 6.00 19.00 14
Dia dip (mmHg) 16.71 7.07 15.50 5.00 31.00 14
Total body water % 53.96 3.67 54.20 47.00 59.00 14
BMI (kg/m2) 23.15 2.77 22.85 18.10 28.40 14
Fat % 22.04 6.00 19.90 14.00 32.80 14
Fat mass (kg) 15.30 4.61 16.45 7.90 23.00 14
Muscle mass (kg) 51.56 11.27 46.95 38.00 77.00 14
Visceral fat rating 3.93 2.37 4.00 1.00 8.00 14
OGTT GLC1 (mmol/l) 4.40 0.40 4.35 3.80 5.10 14
OGTT GLC2 (mmol/l) 3.90 0.62 3.90 2.70 4.80 14
GLP-1 visit 1 (pmol/l) 3.29 5.92 0.85 0.00 17.00 14
TSH visit 1 (mIU/l) 1.41 0.66 1.37 0.50 2.90 14
SD standard deviation, BP blood pressure, Syst systolic, Dia diastolic, Dip dipper, BMI body mass index, OGTT oral glucose
tolerance test, GLC glucose, GLP-1 glucagon-like peptide-1, TSH thyrotropin hormone
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rating (VFR)]. Bioimpedance was measured
using a Tanita body composition analyzer
(model SC-330, Tanita Europe BV, Amsterdam,
Netherlands).
Study Design
Before being enrolled in the study (screening),
participants completed a medical history inter-
view. They were instructed to come the fol-
lowing day for their first visit while fasting.
Randomization was performed by a coworker
not included in the study (8 patients were ran-
domized to receive infusion with GLP-1 first
and than placebo; another 7 patients were ran-
domized to receive placebo first and then infu-
sion with GLP-1).
The study protocol included two visits sepa-
rated by at least 7 days.
Blood was drawn for laboratory analysis and
routine physical examination.
On the second visit day, participants arrived
at the research unit in the morning after an
overnight fast. Initially, an oral saline load was
delivered in the form of a standardized meal
(soup). The soup was consumed in 30 min. After
that, the participants were instructed to drink
1/2 l of bottled water during the following 1 h.
In addition to the soup and water, a saline
infusion with or without GLP-1 (1.5 pmol/kg/
min) was given at a rate of 0.06 ml/kg/min for
3 h from the beginning of the oral sodium load.
The investigators and nurses performing the
procedure were blinded to the test conditions;
the solutions were prepared by a technician not
involved with the study participants. Blood
samples were drawn 180 and 360 min from the
beginning of infusion (Fig. 1). The following
parameters were measured at both time points:
glucose, insulin, PRA, aldosterone, GLP-1, and
ADH. After 6 h, the sodium, chloride, calcium,
creatinine, and osmolality were measured in
urine.
Patients were instructed to return after at
least 7 days for a third visit, fasting as before.
The same procedure carried out in visit 2 was
performed at visit 3, but if they received a saline
infusion with GLP-1 at visit 2 they received a
saline infusion without GLP-1 at visit 3, and
vice versa.
Materials
Synthetic human GLP-1 was obtained from
Bachem (Bubendorf, Switzerland). Peptide con-
tent was administered at a calculated dosage of
1.5 pmol/kg/min dissolved in 500 ml 0.9% sal-
ine solution. The placebo infusion was 0.9%
saline solution. The oral sodium load was
delivered in the form of 0.5 l soup containing
12 g NaCl (it contained 4680 mg, i.e.,
203,58 mmol/l of sodium), which is approxi-
mately the average daily intake of salt per adult
in Croatia [14]. The ingested soup included
virtually no fat, proteins, or sugar, and only a
small amount of flavor enhancer (monosodium
glutamate) and artificial food coloring. The
soup concentrate was dissolved in standard
bottled water. Bottled water of the same brand
(500 ml of natural artesian water, cal-
cium/magnesium ratio 2:1, pH 7.4) was served
as a beverage after the soup.
Blood for GLP-1 assessment was drawn
through an antecubital cannula into syringes
with EDTA (6 mol/l) and aprotinin (1000 kIU/l)
and kept on ice. After centrifugation, the
plasma samples were kept frozen at -20 C until
analysis. GLP-1 was determined using the Active
GLP-1 (7–36) ELISA ALPCO (Salem, USA) diag-
nostic kit.
Blood for ADH assessment was drawn
through an antecubital cannula into syringes
and kept on ice. After centrifugation, the
plasma samples were kept frozen at -20 C until
analysis. ADH was determined using Cayman
Chemical’s (Ann Arbor, Michigan, USA) argi-
nine vasopressin EIA diagnostic kit.
Methods
The data were analyzed using descriptive
statistics, the chi-square test, the two-sample t-
test, analysis of variance (ANOVA), and corre-
lation analysis. Descriptive statistics were used
to describe the basic features of the sample in
the study (proportions for categorical data and
mean ± standard deviation for normally
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distributed continuous variables, or median and
interquartile range for variables deviating from
the normal distribution). For continuous vari-
ables, the independent t-test or ANOVA (for two
or more groups) was used. For repeated mea-
sures (paired samples), we used the paired t-test
for two measurements or a repeated-measures
ANOVA for three or more measurements. Sta-
tistical analysis was performed using SPSS 15.0
(SPSS, Chicago, USA), with the level of statistical
significance set at p\0.05.
RESULTS
Some of the participants had baseline (at visit 1)
ADH and aldosterone levels above the normal
ranges. Mean aldosterone was 241.57 pmol/l
(normal range 96–541), and two participants
had basal aldosterone above the upper limit,
though the presence of normal PRA/aldosterone
excluded primary hyperaldosteronism in these
individuals. Mean ADH was 2.08 pg/ml (normal
range 0.4–5.2), and one participant had an ADH
level above the normal range, but normal serum
baseline electrolyte levels excluded inappropri-
ate ADH secretion syndrome in this participant.
Biochemical parameters at baseline (visit 1)
and at 3 and 6 h in patients receiving the pla-
cebo, and in patients receiving the GLP-1 infu-
sion, were compared by repeated-measures
ANOVA (Table 2). After GLP-1 infusion, aldos-
terone decreased by a statistically significant
amount (p\ 0.008) after 3 h compared to the
baseline level (Fig. 2).
Insulin also decreased by a statistically sig-
nificant amount 3 h after GLP-1 infusion
(p\ 0.001) and 6 h after saline infusion
(p\ 0.001) compared to the baseline level.
No statistically significant differences were
observed in any of the other measured param-
eters considered in the study.
Fig. 1 Study protocol
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There was no positive correlation between the
observed change in aldosterone level (aldos-
terone level 3 h after GLP-1 infusion compared to
baseline) and any of the following variables: age,
average systolic blood pressure, average diastolic
blood pressure, overnight systolic dipper and
overnight diastolic dipper percentages, TSH,
glucose in OGTT (glucose at first or second time
point), base value of GLP-1, BMI, mean fat per-
centage, fat mass, muscle mass, VFR, or TBW.
No statistically significant correlations or
sex-related differences were found between any
of the tested parameters.
There was a significant decrease in median
insulin during placebo infusion after 6 h
(p = 0.011) and a decrease in median insulin
during GLP-1 infusion after 3 h (p = 0.016)
compared to the baseline insulin level. There
was no positive correlation between the
observed change in insulin level (insulin level
Table 2 Results of repeated-measures ANOVA of the measured parameters comparing values obtained at baseline (visit 1),
3, and 6 h after saline infusion and after GLP-1 infusion
Mean SD Median Min Max N F ratio, p value
Aldo visit 1 (pmol/l) 241.57 113.43 219.00* 96.00 541.00 14 F(2.5.29.3) = 5.414.
p = 0.008Aldo saline 3 h (pmol/l) 134.64 52.82 133.50 82.00 256.00 14
Aldo saline 6 h (pmol/l) 154.64 65.40 140.00 80.00 291.00 14
Aldo GLP-1 3 h (pmol/l) 136.71 50.38 129.00* 82.00 234.00 14
Aldo GLP-1 6 h (pmol/l) 182.93 107.99 150.50 86.00 466.00 14
PRA visit 1 (ug/l/h) 0.62 0.30 0.55 0.20 1.30 14 F(4.52) = 2.078.
p = 0.097PRA saline 3 h (ug/l/h) 0.72 0.41 0.65 0.20 1.50 14
PRA saline 6 h (ug/l/h) 0.87 0.49 0.80 0.30 1.70 14
PRA GLP-1 3 h (ug/l/h) 0.51 0.26 0.50 0.10 1.20 14
PRA GLP-1 6 h (ug/l/h) 0.72 0.47 0.71 0.10 2.00 14
ADH visit 1 (pg/ml) 2.08 338.22 122.00 45.00 1371.00 14 F(1.9.25.2) = 2.410
p = 0.112ADH saline 3 h (pg/ml) 1.24 66.95 108.00 44.00 254.00 14
ADH saline 6 h (pg/ml) 2.23 389.95 88.50 41.00 1554.00 14
ADH GLP-1 3 h (pg/ml) 5.24 794.99 122.00 43.00 2304.00 14
ADH GLP-1 6 h (pg/ml) 3.48 434.61 125.00 41.00 1267.00 14
Insulin visit 1 (mU/l) 7.48 3.49 6.90* 3.00 17.00 14 F(1.8.23.9) = 9.225
p = 0.001Insulin saline 3 h (mU/l) 4.2 1.75 4.2 1.3 7.7 14
Insulin saline 6 h (mU/l) 4.16 1.5 4.10* 2.3 7.6 14
Insulin GLP-1 3 h (mU/l) 3.89 1.49 4.03 1.4 7.1 14
Insulin GLP-1 6 h (mU/l) 4.64 2.23 4.00* 2.2 9.5 14
Na GLP-1 132.36 73.28 119.00 29.00 245.00 14 F(1.13) = 1.832
p = 0.199Na in saline 112.14 73.92 93.00 34.00 250.00 14
Bold measures are showing values with statistical signiﬁcance
Aldo aldosterone, PRA plasma renin activity, ADH antidiuretic hormone, GLP-1 glucagon-like peptide-1, SD standard
deviation
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3 h after placebo infusion compared to the
baseline insulin level or the insulin level 6 h
after GLP-1 infusion compared to the baseline
insulin level) and any of the previously men-
tioned laboratory and anthropometric variables
(age, average systolic blood pressure, average
diastolic blood pressure, overnight systolic dip-
per and overnight diastolic dipper percentages,
TSH, glucose in OGTT (glucose at first or second
time point), basal value of GLP-1, BMI, mean fat
percentage, fat mass, muscle mass, VFR, or
TBW).
There was no significant difference between
healthy males and females in any observed
parameter (GLP-1, aldosterone, PRA, glucose,
insulin, or urine sodium) at any follow-up point
(all p[0.05).
DISCUSSION
We demonstrated that GLP-1 infusion signifi-
cantly decreased aldosterone after 3 h in 14
healthy participants, confirming the influence
of incretins on the RAAS.
Skov et al. [13] demonstrated that GLP-1
significantly reduced the circulating concen-
tration of angiotensin II by 19%, without pro-
ducing significant changes in either PRA or the
aldosterone level. This effect was attributed to
the direct action of GLP-1 on the juxta-
glomerular apparatus through changes in renal
dynamics and/or the downregulation of angio-
tensin II production in GLP-1-responsive tissues
(i.e., local RAAS cellular production) [15]. One
possible explanation for the downregulation of
angiotensin II by GLP-1 is the inhibition of
angiotensin II through the action of GLP-1 on
protein kinase A-dependent phosphorylation.
In our study, the decrease in aldosterone 3 h
after GLP-1 infusion may be explained by the
direct action of GLP-1 on its receptors in kidney
tissue and the inhibition of angiotensin II. In a
study by Sedam et al. [16], the long-term
administration of liraglutide increased aldos-
terone levels. That study showed that
Fig. 2 Suppression of aldosterone following infusion of GLP-1
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aldosterone tended to increase after chronic
dosing with liraglutide, yet the aldosterone-to-
PRA ratio remained unchanged. Although
existing studies have conflicting results, they
indicate an association between GLP-1 and the
RAAS.
In a large randomized controlled trial com-
prising 9340 patients with type 2 diabetes and a
high cardiovascular risk, liraglutide was com-
pared to placebo (added to standard diabetes
care, followed for 3.84 years) [17]. The liraglu-
tide group had lower rates of development and
progression of diabetic kidney disease as well as
lower rates of new-onset persistent microalbu-
minuria. The benefits of liraglutide to the kid-
ney are consistent with its known effects on
traditional risk factors for progressive kidney
disease, including its ability to reduce glucose,
blood pressure, insulin levels, and body weight,
but it seems likely that something else con-
tributes to these effects as well—perhaps the
suppression of the RAAS.
Suppressing the RAAS in type 2 DM patients
with hypertension and normoalbuminuria
using angiotensin-converting enzyme inhibi-
tors or angiotensin receptor blockers decreased
the risk of developing microalbuminuria [18] in
a manner similar to that seen in the liraglutide
trial. Since new-onset microalbuminuria is an
early indicator of diabetic nephropathy,
administration of GLP-1 agonists delayed the
onset of chronic kidney disease.
GLP-1 infusion caused a decrease in insulin
after 3 h. Native GLP-1 in the serum decreases
rapidly (with a half-life of several minutes) due
to the presence of the enzyme dipeptidyl pep-
tidase IV (DPP-IV) [19]. GLP-1 acts on b cells
shortly after it has been infused, which is why
the effect was observed after 3 h but not after
6 h. This is also in agreement with the obser-
vation that GLP-1 enhances insulin secretion in
healthy people [20]. The decreased insulin
levels following placebo infusion after 6 h of
fasting (participants fasted overnight and then
ingested only salty soup and water during the
trial) was an expected result and a consequence
of decreased blood glucose due to the prolonged
fasting state.
Limitations
The sample size of the study was relatively
small. It was limited due to the expense of the
study protocol, the testing procedures applied,
and the availability of participants, since repe-
ated measures were needed to obtain data.
Hemodynamic and renal function parameters
were not evaluated (i.e., the effect on blood
pressure, heart rate, changes in albuminuria or
renal function). However, GLP-1 infusion into a
healthy individual has only a short-term effect,
so it is unlikely that these parameters would
have changed significantly.
CONCLUSION
Glucagon-like peptide-1 receptor agonists are
widely used as effective and safe antidiabetic
medications. As well as their effects on glucose-
dependent insulin secretion, they play other
roles. Their positive influence on blood pressure
and the development of kidney disease is
attributed to many different mechanisms, not
only to glycemic control. There have not been
many studies of the basic mechanistic outcome
of native GLP-1. The present study showed that
native GLP-1 can decrease aldosterone secretion
in a group of healthy individuals, supporting
the idea that GLP-1-activating agents have
beneficial outcomes on blood pressure and the
RAAS.
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